Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec;35(3):862-886.
doi: 10.1007/s12028-021-01311-3. Epub 2021 Aug 2.

Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage

Kathryn N Kearns #  1 , Natasha Ironside #  1 , Min S Park  1 , Bradford B Worrall  2 , Andrew M Southerland  2 , Ching-Jen Chen  1 , Dale Ding  3
Affiliations
Review

Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage

Kathryn N Kearns et al. Neurocrit Care. 2021 Dec.

Abstract

Patients who survive the initial ictus of spontaneous intracerebral hemorrhage (ICH) remain vulnerable to subsequent injury of the perilesional parenchyma by molecular and cellular responses to the hematoma. Secondary brain injury after ICH, which contributes to long-term functional impairment and mortality, has emerged as an attractive therapeutic target. This review summarizes preclinical and clinical evidence for neuroprotective therapies targeting secondary injury pathways following ICH. A focus on therapies with pleiotropic antiinflammatory effects that target thrombin-mediated chemotaxis and inflammatory cell migration has led to studies investigating statins, anticholinergics, sphingosine-1-phosphate receptor modulators, peroxisome proliferator activated receptor gamma agonists, and magnesium. Attempts to modulate ICH-induced blood-brain barrier breakdown and perihematomal edema formation has prompted studies of nonsteroidal antiinflammatory agents, matrix metalloproteinase inhibitors, and complement inhibitors. Iron chelators, such as deferoxamine and albumin, have been used to reduce the free radical injury that ensues from erythrocyte lysis. Stem cell transplantation has been assessed for its potential to enhance subacute neurogenesis and functional recovery. Despite promising preclinical results of numerous agents, their outcomes have not yet translated into positive clinical trials in patients with ICH. Further studies are necessary to improve our understanding of the molecular events that promote damage and inflammation of the perihematomal parenchyma after ICH. Elucidating the temporal and pathophysiologic features of this secondary brain injury could enhance the clinical efficacy of neuroprotective therapies for ICH.

Keywords: Clinical trial; Intracerebral hemorrhage; Neuroprotection; Secondary injury; Stroke.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ziai WC. Hematology and inflammatory signaling of intracerebral hemorrhage. Stroke. 2013;44:S74–8. - PubMed
    1. Keep RF, Hua Y, Xi G. Intracerebral haemorrhage: Mechanisms of injury and therapeutic targets. Lancet Neurol. 2012;11:720–31. - PubMed
    1. Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol. 2006;5:53–63. - PubMed
    1. Chen CJ, Ding D, Ironside N, Buell TJ, Southerland AM, Koch S, et al. Cigarette smoking history and functional outcomes after spontaneous intracerebral hemorrhage. Stroke. 2019;50:588–94. - PubMed - PMC
    1. Ironside N, Chen CJ, Ding D, Mayer SA, Connolly ES. Perihematomal edema after spontaneous intracerebral hemorrhage. Stroke. 2019;50:1626–33. - PubMed

MeSH terms

Substances

LinkOut - more resources